Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Large-Cell, Anaplastic

Explore clinical trials studying Lymphoma, Large-Cell, Anaplastic. Study availability and eligibility vary by location and protocol.

289 public trials 18 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Large-Cell, Anaplastic trial results

Active, Not Recruiting

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

NCT03598998

Conditions
Anaplastic Large Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Hemic and Lymphatic Diseases, +35 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • University of Nebraska Medical Center Omaha, Nebraska, United States
View Trial Details
Active, Not Recruiting

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

NCT02978625

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Anaplastic Large Cell Lymphoma, ALK-Positive, +86 more
Locations
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • Keck Medical Center of USC Pasadena Pasadena, California, United States
View all 36 locations
View Trial Details
Active, Not Recruiting

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

NCT06035497

Conditions
Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +26 more
Locations
  • Local Institution - 0031 Anjo-shi, Aichi-ken, Japan
  • Local Institution - 0011 Nagoya, Aichi-ken, Japan
  • Local Institution - 0024 Toyohashi, Aichi-ken, Japan
  • Local Institution - 0017 Kamogawa, Chiba, Japan
View all 40 locations
View Trial Details
Active, Not Recruiting

Crizotinib Continuation Clinical Study

NCT05160922

Conditions
ALCL, Bronchial Neoplasms, Carcinoma, Bronchogenic, +24 more
Locations
  • Cancer Hospital Chinese Academy of Medical Science Beijing, Beijing Municipality, China
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Fujian Province Oncology Hospital Fuzhou, Fujian, China
  • Sun Yat-Sen University Cancer center Guangzhou, Guangdong, China
View all 13 locations
View Trial Details
Active, Not Recruiting

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

NCT03113500

Conditions
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, +26 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • M D Anderson Cancer Center Houston, Texas, United States
View Trial Details
Active, Not Recruiting

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

NCT04526834

Conditions
Anaplastic Large Cell Lymphoma, Diffuse Large B Cell Lymphoma, Extranodal NK/T-cell Lymphoma, +17 more
Locations
  • City of Hope Duarte, California, United States
  • Sarah Cannon Research Institute Nashville, Tennessee, United States
  • Baylor College of Medicine Houston, Texas, United States
  • The University of Texas MD Anderson Cancer Centre Houston, Texas, United States
View Trial Details

Related conditions